AstraZeneca wins FDA breakthrough status for durvalumab
LONDON: The U.S. Food and Drug Administration has granted breakthrough therapy designation to AstraZeneca's biggest new drug hope durvalumab as a treatment in bladder cancer, the drugmaker said on.The experimental medicine is a so-called PD-L1 therapy that fights cancer by boosting the immune system.Breakthrough therapy designation expedites the development and review of medicines intended...
Login or Register to read the full article
LONDON: The U.S. Food and Drug Administration has granted breakthrough therapy designation to AstraZeneca's biggest new drug hope durvalumab as a treatment in bladder cancer, the drugmaker said on.
The experimental medicine is a so-called PD-L1 therapy that fights cancer by boosting the immune system.
Breakthrough therapy designation expedites the development and review of medicines intended to treat serious or life-threatening diseases.
Durvalumab is also being developed as a treatment for lung, head and neck, gastric, pancreatic, liver and blood cancers. It faces competition from rival products made by Bristol-Myers Squibb, Merck and Roche.
The experimental medicine is a so-called PD-L1 therapy that fights cancer by boosting the immune system.
Breakthrough therapy designation expedites the development and review of medicines intended to treat serious or life-threatening diseases.
Durvalumab is also being developed as a treatment for lung, head and neck, gastric, pancreatic, liver and blood cancers. It faces competition from rival products made by Bristol-Myers Squibb, Merck and Roche.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd